SPRB (Spruce Biosciences) Total Liabilities: $21.52 Mil (As of Mar. 2026)

What is Spruce Biosciences Total Liabilities?

Spruce Biosciences SPRB -0.07% 40 Total Liabilities is $21.52 Mil as of Mar. 2026. GuruFocus rates SPRB with a GF Score™ of 40/100 and a GF Value™ of $4.08 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Spruce Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 was $21.52 Mil.

Spruce Biosciences's quarterly Total Liabilities increased from Sep. 2025 ($9.93 Mil) to Dec. 2025 ($10.51 Mil) and increased from Dec. 2025 ($10.51 Mil) to Mar. 2026 ($21.52 Mil).

Spruce Biosciences's annual Total Liabilities declined from Dec. 2023 ($27.44 Mil) to Dec. 2024 ($16.39 Mil) and declined from Dec. 2024 ($16.39 Mil) to Dec. 2025 ($10.51 Mil).

Spruce Biosciences Total Liabilities Related Terms

Spruce Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Spruce Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spruce Biosciences Total Liabilities Chart

Spruce Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

15.12

17.16

27.44

16.39

10.51

Spruce Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															16.33	8.64	9.93	10.51	21.52

40GF Score

Spruce Biosciences Inc SPRB

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Spruce Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Spruce Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	10.086	+	(0.419	+	4.9960036108132E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	10.51

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	53.021	-	42.516
	=	10.51

Spruce Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.784	+	(5.796	+	3.938
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	21.52

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	56.166	-	34.648
	=	21.52

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $21.52 Mil mean?

Spruce Biosciences (SPRB) has a Total Liabilities of $21.52 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Spruce Biosciences and its competitors.

Is Spruce Biosciences' Total Liabilities too high?

Spruce Biosciences' current Total Liabilities is $21.52 Mil. Overall, Spruce Biosciences has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Spruce Biosciences' Total Liabilities compare to TLSA and MIST?

Spruce Biosciences' Total Liabilities of $21.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Spruce Biosciences and its competitors. Spruce Biosciences's current Total Liabilities is $21.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Spruce Biosciences stock overvalued right now?

Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $52.51 — trading 1187% above its estimated fair value. The current Total Liabilities is $21.52 Mil. Spruce Biosciences' overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current Total Liabilities is $21.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spruce Biosciences (SPRB) Overvalued in 2026?

Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued. The current stock price of $52.51 is trading 1187% above its estimated GF Value™ of $4.08. GuruFocus considers Spruce Biosciences to be Significantly Overvalued.

Key valuation signals for SPRB:

Total Liabilities: $21.52 Mil
GF Value™: $4.08 vs. price of $52.51 (1187% above fair value)
GF Score™: 40/100 with 1 warning sign

No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spruce Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies TLSA MIST TNYA NRXP HURA ACOG CRBP PRQR MENS ENLV VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080

Website https://www.sprucebiosciences.com

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.

40GF Score

Get the complete analysis for SPRB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$52.51

Price

$4.08

GF Value

View SPRB Analysis

See Total Liabilities data for all stocks →